TY - JOUR T1 - The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism JO - Nefrología (English Edition) T2 - AU - Egido,Jesús AU - Martínez-Castelao,Alberto AU - Bover,Jordi AU - Praga,Manuel AU - Torregrosa,José Vicente AU - Fernández-Giráldez,Elvira AU - Solozábal,Carlos SN - 20132514 M3 - 10.1016/j.nefroe.2016.02.006 DO - 10.1016/j.nefroe.2016.02.006 UR - https://www.revistanefrologia.com/en-the-pleiotropic-effects-paricalcitol-beyond-articulo-S2013251416000274 AB - Secondary hyperparathyroidism (SHPT) is a common complication in patients with chronic kidney disease (CKD) that is characterised by elevated parathyroid hormone (PTH) levels and a series of bone-mineral metabolism anomalies. In patients with SHPT, treatment with paricalcitol, a selective vitamin D receptor activator, has been shown to reduce PTH levels with minimal serum calcium and phosphorus variations. The classic effect of paricalcitol is that of a mediator in mineral and bone homeostasis. However, recent studies have suggested that the benefits of treatment with paricalcitol go beyond PTH reduction and, for instance, it has a positive effect on cardiovascular disease and survival. The objective of this study is to review the most significant studies on the so-called pleiotropic effects of paricalcitol treatment in patients with CKD. ER -